Defining Current Patterns of Blood Product Use during Intensive Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients.

INTRODUCTION

Blood product transfusion retains a critical role in the supportive care of patients with acute myeloid leukemia (AML). Whereas previous studies have shown increased transfusion dependency to portend inferior outcome, predictive factors of an increased transfusion burden and the prognostic impact of transfusion support have not been assessed recently.

METHODS/PATIENTS: We performed a retrospective analysis on a recent cohort of patients given intensive induction chemotherapy in 2014-2022.

RESULTS

The analysis comprised 180 patients with a median age of 57 years with 80% designated as de novo AML. Fifty-four patients (31%) were mutated, and 73 patients (42%) harbored . Favorable risk and intermediate risk ELN 2017 patients accounted for 43% and 34% of patients, respectively. The median number of red blood cell (RBC) and platelet units given during induction were 9 and 7 units, respectively. Seventeen patients (9%) received cryoprecipitate, and fresh frozen plasma (FFP) was given to 12 patients (7%). Lower initial hemoglobin and platelet levels were predictive of increased use of RBC ( < 0.0001) and platelet transfusions ( < 0.0001). FFP was significantly associated with induction related mortality (42% vs. 5%; < 0.0001) and with (72% vs. 28%; = 0.004). Blood group AB experienced improved mean overall survival compared to blood group O patients (4.1 years vs. 2.8 years; = 0.025). In multivariate analysis, increased number of FFP (hazard ratio [HR], 4.23; 95% confidence interval [CI], 2.1-8.6; < 0.001) and RBC units (HR, 1.8; 95% CI, 1.2-2.8; = 0.008) given was associated with inferior survival.

CONCLUSION

Transfusion needs during induction crucially impact the clinical trajectory of AML patients.